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Study of Heart and Renal Protection (SHARP). Among pa- dialysis patients, angina in about one quarter, and a his-
tients with preexisting coronary heart disease, large-scale ran- tory of myocardial infarction (MI) in about 10% [2]. The
domized trials have demonstrated that lowering low-density available evidence suggests that such disease is presentlipoprotein (LDL)-cholesterol concentration by about 1 mmol/L
very early in the natural history of CKD. In prospectivefor 4–5 years reduces the risk of coronary events and strokes
observational studies among predialysis patients, for ex-by about 25%. Patients with established chronic kidney disease
(CKD) are at high risk of vascular disease, so the benefits of ample, about one third of those with moderate reduction
cholesterol-lowering therapy might be expected to be substan- in glomerular filtration rate (GFR) equivalent to CKD
tial in this population. Patients with CKD have generally been
Stage 3 (GFR 60–89 mL/min/1.73m2) have been foundexcluded from previous trials, however, and there is currently
to have a history of overt cardiovascular disease [2].no reliable randomized evidence that lowering LDL-choles-
terol would be beneficial among them.
There are several reasons why the demonstrated benefits
ABSENCE OF EVIDENCE ON CHOLESTEROL-of lowering blood cholesterol in other populations might not
translate to patients with CKD. First, observational studies LOWERING IN CKD PATIENTS
among dialysis patients have reported a negative association
Among patients with CHD but without evidence ofbetween blood total cholesterol and mortality. Second, only
CKD, large-scale randomized trials have demonstratedabout one quarter of cardiac mortality in such patients appears
to be attributable to acute myocardial infarction, and poten- that lowering LDL-cholesterol concentration by about
tially avoidable with cholesterol lowering, while the other com- 1 mmol/L (about 40 mg/dL) for 4–5 years reduces the risk
mon causes (e.g., cardiac arrest, arrhythmia, and heart failure) of a coronary event by about one quarter [3, 4], and themay not be as dependent on cholesterol levels. Finally, the
risk of ischemic stroke by a similar amount [4, 5]. Patientslong-term safety of cholesterol reduction among patients with
with established CKD have generally been excluded fromCKD remains unclear. Hence, there is an important need for
reliable direct evidence on whether lowering cholesterol pre- such trials, however, and it remains substantially uncertain
vents a worthwhile proportion of vascular events, without unac- whether such patients would benefit when CHD is clini-
ceptable toxicity, among patients with CKD. The Study of cally absent. Currently, the only source of evidence aboutHeart and Renal Protection (SHARP) aims to assess the effects
the effects of lowering cholesterol in CKD patientsof cholesterol-lowering therapy with a combination of simvas-
comes from analyses of small subgroups within previoustatin and the cholesterol-absorption inhibitor ezetimide among
around 9000 patients with CKD. trials. These analyses are of limited value because few
patients with significant renal dysfunction were included
and almost all had established CHD. For example, ifBACKGROUND
patients with CHD are excluded, the Heart Protection
Patients with end-stage renal disease (ESRD) are at Study (HPS) included only 128 patients with significant
high risk for developing premature cardiovascular dis-
renal impairment (i.e., creatinine 150–200 mol/L in
ease. In the general population, most cardiac mortality
men, or 130–200 mol/L in women), and so did not
is attributable to atheromatous coronary heart disease
provide direct evidence about the effects of cholesterol-(CHD), but in dialysis patients much cardiac mortality
lowering therapy in CKD patients without prior CHD.appears to be caused by cardiomyopathy, leading to ar-
rhythmia or congestive heart failure [1]. At least some of
the excess risk of cardiovascular disease develops before EFFECTS OF LOWERING CHOLESTEROL IN
ESRD occurs, since clinical manifestations of congestive CKD PATIENTS ARE UNCERTAIN
heart failure are already present in about one third of new There are several reasons why the demonstrated bene-
fits of lowering blood cholesterol in other populations
might not translate to patients with CKD. First, in otherKey words: randomized trial, cholesterol, ezetimibe, simvastatin, chronic
kidney disease. high-risk populations (such as patients with diabetes),
observational studies have shown that there is a roughly 2003 by the International Society of Nephrology
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Fig. 1. (A ) Associations between blood cholesterol and cardiovascular mortality, plotted on a logarithmic scale, among screenees in the Multiple
Risk Factor Intervention Trial (MRFIT) with diabetes (N  5000) and without diabetes (N  340,000) [6]. (B ) Associations between blood total
cholesterol and all-cause mortality, plotted on a logarithmic scale, among 12,000 hemodialysis patients followed for one year [7].
log-linear relationship between risk of death from car- domized trials (mostly testing statins) among CKD pa-
diovascular disease and blood cholesterol (Fig. 1A) [6], tients suggested that lowering LDL-cholesterol might
but an analogous association has not been demonstrated reduce the rate of loss of GFR [10]. In order to confirm
among patients with CKD. One large study among dial- or refute this hypothesis properly, a large-scale trial of
ysis patients reported a negative association at very low cholesterol-lowering therapy in such patients is needed.
cholesterol levels (which are common in dialysis pa-
tients), and a flat relationship at cholesterol levels within
STUDY OF HEART AND RENALthe “normal” range (Fig. 1B) [7]. Among dialysis patients
PROTECTION (SHARP)with very low cholesterol, a negative association between
The Study of Heart and Renal Protection (SHARP)cholesterol and mortality may be due to “reverse causal-
is a large-scale randomized trial designed to assess theity,” with malnutrition and other chronic disease both
effects of lowering cholesterol on major vascular events,lowering blood cholesterol and, independently, increas-
and on the rate of progression to ESRD among patientsing the risk of death [1]. Such a phenomenon is less likely,
with CKD. Prior to commencing this study, two pilothowever, to explain the absence of an association among
studies were conducted in order to establish importantthose with “average” cholesterol levels (Fig. 1B).
information about the safety and biochemical efficacy ofSecond, only about one quarter of cardiac mortality
cholesterol lowering in patients with CKD, and to assessin CKD patients appears to be definitely attributable to
the feasibility of large-scale recruitment of such patients.acute myocardial infarction, and potentially avoidable
with cholesterol-lowering, while the other common causes
(e.g., cardiac arrest, arrhythmia, and heart failure) may
THE FIRST HARP PILOT STUDY (UK-HARP-I)not be as dependent on cholesterol levels. Finally, the
In the first pilot study (UK-Heart and Renal Protec-long-term safety of cholesterol reduction among patients
tion [UK-HARP-I]), a total of 448 patients with CKDwith CKD remains unclear. Hence, there is a need for
were randomized to simvastatin 20 mg daily versusreliable direct evidence on whether lowering cholesterol
matching placebo (and, in a factorial design, aspirin 100among patients with CKD prevents a worthwhile propor-
mg daily versus matching placebo) with treatment con-tion of major vascular events without unacceptable tox-
tinuing for 1 year [11]. At baseline, a total of 242 patientsicity.
were predialysis with plasma creatinine150mol/L, 73Because patients with established CKD are at high risk
were receiving maintenance hemodialysis or peritonealof vascular disease, the benefits of cholesterol-lowering
dialysis, and 133 patients had a functioning renal trans-therapy may well be substantial in this population. More-
plant. Overall, simvastatin 20 mg daily reduced LDL-over, it has been suggested that HMG-CoA reductase
cholesterol by 26% (P  0.0001) from a baseline meaninhibitors (“statins”) may be particularly effective among
of 3.2 mmol/L, which is similar to the LDL-cholesterolCKD patients because of their non-lipid (e.g., antiprolif-
reduction produced by simvastatin 20 mg daily amongerative) effects [8]. For example, in animal models, glo-
patients without CKD [12]. Allocation to simvastatinmerulosclerosis may be promoted by certain blood lipid
abnormalities [9], and a meta-analysis of small-scale ran- was not associated with any significant excess risk of
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abnormal liver transaminases, or of elevated creatine lowering therapy on major vascular events, the second
kinase, and there were no cases of serious myopathy HARP pilot study (UK-HARP-II) will compare ezeti-
(defined as muscle pain with creatine kinase 10 times mibe/simvastastin versus simvastatin (20 mg daily) for 6
the upper limit of normal) [11]. months among 203 patients with CKD. The principal
aims are to assess the effects of ezetimibe on tolerability
(e.g., unexplained muscle symptoms), markers of safetyNEED FOR MORE INTENSIVE
(differences in alanine transaminase, creatine kinase,CHOLESTEROL REDUCTION
creatinine, calcium, phosphate, lipid-soluble vitamins),
In randomized trials comparing a statin versus placebo and biochemical efficacy (differences in lipid profile) in
in other high-risk populations, the size of the proportional CKD patients. Preliminary results indicate that the com-
reduction in CHD events appears to be roughly propor- bination is well tolerated in patients with CKD, and that
tional to the mean absolute difference in LDL-choles- it produces proportional reductions in LDL-cholesterol
terol achieved during the trial [3, 4, 13]. Any given daily that are similar in size to those achieved by the combina-
statin dose has been found to produce a fixed propor- tion in patients who do not have CKD.
tional reduction in LDL-cholesterol, irrespective of the
presenting level of LDL-cholesterol. Hence, the mean
absolute difference in LDL-cholesterol depends directly THE STUDY OF HEART AND RENAL
on the baseline LDL-cholesterol level. Patients with PROTECTION (SHARP)
CKD generally have “average” or even “below average” The Study of Heart and Renal Protection (SHARP)
LDL-cholesterol levels, and so may require a choles- aims to compare ezetimibe/simvastatin versus placebo
terol-lowering regimen that can produce a substantial among around 9000 patients with CKD (approximately
proportional reduction—and hence a correspondingly 6000 of whom will be predialysis, and 3000 undergoing
large absolute reduction—in LDL-cholesterol in order dialysis), with treatment scheduled to continue for at
to produce a worthwhile reduction in cardiac events. least 4 years. The primary aim of SHARP is to assess
Although this could be achieved by increasing the statin the effects of lowering LDL-cholesterol on the time to
dose in patients with CKD, this may result in an increased
a first “major vascular event” (defined as nonfatal myo-
risk of muscle toxicity. In such patients, therefore, a safer
cardial infarction or cardiac death, nonfatal or fatal
way to produce additional reductions in LDL-cholesterol
stroke, or revascularization). Secondary aims of thewould be particularly valuable.
study include an assessment of the effects of ezetimibe/The cholesterol absorption inhibitor ezetimibe selec-
simvastatin on progression to ESRD (among predialysistively inhibits the passage of dietary and biliary choles-
patients), various causes of death, major cardiac eventsterol across the intestinal wall [14], and, unlike other
(defined as nonfatal MI or cardiac death), stroke, andcholesterol-lowering drugs which act on the bowel (e.g.,
hospitalization for angina. The effects on major vascularresins), is well tolerated, and does not accumulate sig-
events will also be examined among particular subgroupsnificantly in the blood among patients with CKD since
of patients.it is chiefly excreted via the intestine [15]. In patients
The SHARP study is an investigator-initiated studywith CKD, the combination of ezetimibe 10 mg daily
conducted by an international collaboration of nephrolo-and simvastatin 20 mg daily (“ezetimibe/simvastatin”)
gists and clinical trialists in over 200 hospitals in aboutreduces mean LDL-cholesterol by around one fifth as
10 countries. It is scheduled to commence in mid 2003.compared to simvastatin alone [16, 17]. This equates to
a reduction of around one half as compared to placebo,
which is a slightly greater potency than that of simvas- CONCLUSION
tatin 80 mg daily. Ezetimibe/simvastatin appears to pos-
It is currently unclear whether dyslipidemia in patientssess substantial cholesterol-lowering efficacy while offer-
with CKD contributes to an increased risk of cardiovas-ing the potential for lower toxicity, and is therefore
cular disease among such patients. In particular, therepotentially ideal for patients with CKD.
is a lack of epidemiologic evidence supporting such an
association, and it remains unclear what proportion of
THE SECOND HARP PILOT STUDY OF cardiac disease is atherosclerotic and, hence, potentially
SIMVASTATIN AND EZETIMIBE (UK-HARP-II) avoidable by lowering cholesterol. In the coming years,
SHARP (and other studies in patients with renal disease)Although the combination of simvastatin and ezeti-
should help to answer these outstanding uncertaintiesmibe appears to be well tolerated, the effects of adding
by providing clear information about whether substantialezetimibe to simvastatin have not been widely studied
reductions in LDL-cholesterol reduce the risk of majorin patients with CKD. Therefore, prior to commencing
a large-scale study to assess the effects of cholesterol- vascular events in patients with CKD.
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